<DOC>
	<DOC>NCT00029224</DOC>
	<brief_summary>Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.</brief_summary>
	<brief_title>Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion Criteria Signed informed consent Greater than 18 years of age Proof of breast cancer, multiple myeloma or prostate cancer Diagnosis of at least one cancerrelated bone lesion If patient is of childbearing potential, negative pregnancy test and on a medically recognized form of contraception ECOG performance status of 0,1 or 2 Ability to read, understand and write English or Spanish language Normal renal function Corrected serum calcium equal to or greater than 8mg/dl Exclusion Criteria clinically symptomatic brain metastases hypersensitivity to Zometa or other bisphosphonates pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>bone lesions</keyword>
	<keyword>breast cancer</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>bone metastases</keyword>
	<keyword>pain</keyword>
</DOC>